Nasus Pharma is trading 5.12% down at $3.15, with no clear company-specific catalyst identified for October 13, 2026.
- The healthcare sector is down 1.37%, amid concerns about drug pricing and Johnson & Johnson results; broader market indexes are only modestly lower and are a less persuasive explanation.
- The latest located company news is its September 29 announcement of a Phase 1 study, not a new October 13 catalyst.